Bellecapital International Ltd. Abb Vie Inc. Transaction History

Bellecapital International Ltd.

$484 Million
Q3 2024

A detailed history of Bellecapital International Ltd. transactions in Abb Vie Inc. stock. As of the latest transaction made, Bellecapital International Ltd. holds 57,938 shares of ABBV stock, worth $10.4 Million. This represents 2.36% of its overall portfolio holdings.

Number of Shares

57,938

Previous 57,718 0.38%

Holding current value

$10.4 Million

Previous $9.9 Million 15.58%

% of portfolio

2.36%

Previous 2.18%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 21, 2024	BUY	$163.84 - $199.33 $36,044 - $43,852	220 Added 0.38%	57,938 $11.4 Million
Q2 2024 Jul 19, 2024	BUY	$154.79 - $180.76 $303,233 - $354,108	1,959 Added 3.51%	57,718 $9.9 Million
Q1 2024 May 03, 2024	SELL	$159.82 - $182.1 $796,383 - $907,404	-4,983 Reduced 8.2%	55,759 $10.2 Million
Q4 2023 Jan 22, 2024	BUY	$137.6 - $154.97 $138,563 - $156,054	1,007 Added 1.69%	60,742 $9.41 Million
Q3 2023 Oct 17, 2023	SELL	$133.59 - $154.65 $352,143 - $407,657	-2,636 Reduced 4.23%	59,735 $8.9 Million
Q2 2023 Jul 07, 2023	SELL	$132.51 - $164.9 $43,198 - $53,757	-326 Reduced 0.52%	62,371 $8.4 Million
Q1 2023 Apr 25, 2023	SELL	$144.61 - $166.54 $305,271 - $351,565	-2,111 Reduced 3.26%	62,697 $9.99 Million
Q4 2022 Feb 10, 2023	SELL	$138.31 - $165.87 $252,692 - $303,044	-1,827 Reduced 2.74%	64,808 $10.5 Million
Q3 2022 Nov 07, 2022	SELL	$134.21 - $153.93 $217,554 - $249,520	-1,621 Reduced 2.37%	66,635 $8.94 Million
Q2 2022 Jul 27, 2022	SELL	$137.62 - $174.96 $681,769 - $866,751	-4,954 Reduced 6.77%	68,256 $10.5 Million
Q1 2022 May 03, 2022	BUY	$131.98 - $163.75 $679,828 - $843,476	5,151 Added 7.57%	73,210 $11.9 Million
Q4 2021 Jan 20, 2022	BUY	$107.43 - $135.93 $396,094 - $501,173	3,687 Added 5.73%	68,059 $9.22 Million
Q3 2021 Oct 21, 2021	BUY	$106.4 - $120.78 $142,576 - $161,845	1,340 Added 2.13%	64,372 $6.94 Million
Q2 2021 Jul 28, 2021	SELL	$105.21 - $117.21 $620,949 - $691,773	-5,902 Reduced 8.56%	63,032 $7.1 Million
Q1 2021 Apr 13, 2021	BUY	$102.3 - $112.62 $565,105 - $622,112	5,524 Added 8.71%	68,934 $7.46 Million
Q4 2020 Jan 14, 2021	BUY	$80.49 - $108.67 $279,541 - $377,410	3,473 Added 5.79%	63,410 $6.79 Million
Q3 2020 Oct 16, 2020	BUY	$85.91 - $100.83 $422,075 - $495,377	4,913 Added 8.93%	59,937 $5.25 Million
Q2 2020 Jul 16, 2020	SELL	$73.37 - $98.18 $25,899 - $34,657	-353 Reduced 0.64%	55,024 $5.4 Million
Q1 2020 Apr 24, 2020	BUY	$64.5 - $97.79 $383,388 - $581,263	5,944 Added 12.02%	55,377 $4.22 Million
Q4 2019 Feb 12, 2020	BUY	$72.13 - $90.25 $336,774 - $421,377	4,669 Added 10.43%	49,433 $4.38 Million
Q3 2019 Oct 22, 2019	BUY	$62.98 - $75.72 $42,007 - $50,505	667 Added 1.51%	44,764 $3.39 Million
Q2 2019 Jul 22, 2019	SELL	$65.7 - $83.98 $288,882 - $369,260	-4,397 Reduced 9.07%	44,097 $3.21 Million
Q1 2019 Apr 23, 2019	BUY	$77.14 - $90.79 $38,955 - $45,848	505 Added 1.05%	48,494 $3.91 Million
Q4 2018 Feb 07, 2019	BUY	$77.85 - $96.01 $18,372 - $22,658	236 Added 0.49%	47,989 $4.42 Million
Q3 2018 Oct 12, 2018	SELL	$88.91 - $98.84 $270,908 - $301,165	-3,047 Reduced 6.0%	47,753 $4.52 Million
Q2 2018 Jul 10, 2018	BUY	$89.78 - $106.23 $1.78 Million - $2.1 Million	19,798 Added 63.86%	50,800 $4.71 Million
Q1 2018 Apr 24, 2018	SELL	$92.01 - $123.21 $721,634 - $966,336	-7,843 Reduced 20.19%	31,002 $2.93 Million
Q4 2017 Feb 06, 2018	BUY	$89.56 - $98.21 $2.71 Million - $2.97 Million	30,242 Added 351.53%	38,845 $3.76 Million
Q3 2017 Oct 25, 2017	BUY	$69.85 - $89.22 $600,919 - $767,559	8,603	8,603 $764,000

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bellecapital International Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Bellecapital International Ltd. with notifications on news.

Account

Bellecapital International Ltd. Abb Vie Inc. Transaction History